Opposite rays
Atmospheric Optics
2012.10.10 21:48 Atmospheric Optics
Atmospheric Optics. The subreddit for anything related to optic sky phenomena: rainbows, ice halos, aurorae, mirages, cloud iridescence, green flashes, crepuscular rays and spectres of the Brocken.
2008.09.07 23:25 America's Pastime
The subreddit for the bat-and-ball sport played between two teams of nine players. America's Pastime. Mike Trout **For the best user experience, we recommend disabling the Reddit redesign.**
2023.03.25 04:30 VAhippychick Six weeks out from ORIF for a Fibula break.
Has anyone had PT make them worse? I don’t know if it’s just normal healing stuff where it goes back and forth in progress but in the past week I’ve been in consistent pain. My ankle is swollen and I have major cramping that goes through the area that I believe is the syndesmotic joint. That is also where the majority of the swelling is and it goes through to the opposite (inner) side of my ankle.
I had a follow up with my ortho a few days ago and he said random swelling was normal and my X-rays looked great. Cleared me to drive and go without a boot. I told him about my experience that started after PT the week before and he brushed it off and prescribed me celebrex.
Has anyone experienced anything similar? It may almost be worse than the pain right after surgery. I don’t want pain medication. Just a solution.
Thanks for any advice you can give me. Hopeful or not.
submitted by VAhippychick to brokenbones [link] [comments]
I had a follow up with my ortho a few days ago and he said random swelling was normal and my X-rays looked great. Cleared me to drive and go without a boot. I told him about my experience that started after PT the week before and he brushed it off and prescribed me celebrex.
Has anyone experienced anything similar? It may almost be worse than the pain right after surgery. I don’t want pain medication. Just a solution.
Thanks for any advice you can give me. Hopeful or not.
2023.03.24 23:40 MGK_2 So Exciting Watching The Paint Change Color As It Dries
Ladies and Gentlemen, let’s all get ready to watch the paint dry. The shades of crimson and sapphire are deepening, coming through and becoming more defined. Thanks to Kevin0461 on Investors Hangout who was the inspiration of this title.
You can just about feel the Momentum building as Rome falls. Out of the center of the picture, a new day appears as the light rays explode through the forest of trees. That Gumbo Truth Pot yet boils, the roux now is good and ready; the lid shimmers as it rattles. Truth is getting ready to explode, oh, on so many different fronts.
Here are the individuals in the leadership team:
https://www.cytodyn.com/our-team/management-team
Here is the Board of Directors:
https://www.cytodyn.com/our-team/board-of-directors
All contributed in one way or another in providing the requested and necessary information to the FDA. Some more than others, but all had a hand in appropriating CytoDyn’s submission into the format required by the FDA. Their natural resource, the raw material supporting their work, providing the backbone of their documents, was the verified and validated, true and clear, aggregated data vetted by the 4 External FDA Type GCP Auditors. That formatted data had eyes on it by 4 different External FDA Auditors. In addition, the Internal Audit team received the raw, unformatted data from Amarex, and assembled it into the aggregated and formatted data employing the overseeing eye of prior FDA regulators.
In my eyes, I don’t believe that the salvage of the raw data begrudgingly provided by Amarex could have been executed with any more painstaking attention to detail, than the way Cyrus accomplished this task. He brought in (4) External FDA Type GCP Auditors who in former times worked for the FDA, and all (4) auditors approved the data as acceptable to the FDA. Then Cyrus used that data in the submitted documents.
We all know that the FDA is not an easy push over. They warned CytoDyn and Amarex in the past that they would surely deliver an RTF if the BLA was not prepared in accordance with their standards. The FDA lived up to that warning which they made. Here, in the case at hand, the FDA requested 5 documents from CytoDyn and nearing the finale, they requested a 6th document. The identity of the 6th document was not revealed, but the good news so far is that, they posed NO questions about the contents of the 5 documents even though they had been reviewing them as early as October 2022. Will they have questions on the 6th document? Will there be a request for a 7th document? So far, none has been asked and it seems as if the time the FDA has to ask that question is just about up.
The FDA has set the rules of play. As long as you play her game the way she says it has to be played, then you can play. She just wants to know that you will engage in the game the way she wants you to play. She should not care about what you did in your former life, but rather should make those judgments based on how you play today. The FDA gave chances to the old boss, but he never learned her game. Things have changed. The FDA has not changed. She will also give a chance to the new boss. Why? Because she has proof that the things she was concerned about have changed. She has been given the evidence in her own language that Leronlimab is safe & sound and that CytoDyn now behaves in accordance with the rules of her game.
Let us all hope that she hasn’t changed her own rules since the writing of these submissions or since the aggregation of the raw data. That wouldn’t be playing fair, but that would be nothing new, would it? Personally, I don’t think she has anything against CytoDyn, after all; aside from Leronlimab, CytoDyn has been revamped from the ground up. CytoDyn should be looked at in the way the 6 documents reflect the company, as if it has a clean, blank slate and that is what was likely submitted, a picture perfect representation. Clean data. Clean papers. The remembrance and recollection of what it once was should be avoided as all the data is presented new and fresh.
If the FDA considers CytoDyn as the same CytoDyn which it had been under Nader, then, they shall find an issue with the submissions. However, the FDA should go about this without any preconceived notions. They should go about this in an unbiased, unprejudiced manner. Lady Liberty is supposed to be blind. Nobody can pursue a matter and no judge can rule over a matter if there is any personal involvement in any way. Here, the FDA has unlimited power because it is their game and if they are biased against CytoDyn, then, they will find an issue with the submissions.
The FDA let this go for way too long. They knew they didn’t have the proof that Leronlimab was safe, but they also knew that they did not have any evidence of any Severe or Adverse Events. So the trials continued. The trials continued to the point that CytoDyn believed that they had what it would take to file a BLA. CytoDyn thought their Leronlimab was safe because the FDA allowed them to carry on their trials. The FDA warned both CytoDyn and Leronlimab that if their data was not in proper order, they would deny the BLA and issue a RTF in its place. Well, the submitted BLA was not up to par, it was not in order, it did not prove that Leronlimab was safe and the FDA issued an RTF. CytoDyn did not have the data proving that Leronlimab was safe.
Despite this ruling, CytoDyn continued along as if the ruling was not even made, even so far as to conduct Covid 19 trials. CytoDyn and shareholders were still thinking that Leronlimab was safe. The truth was that it would have received RTF on even the Covid 19 trials if they too were submitted, because CytoDyn never proved that Leronlimab was safe. As a results of 2 or 3 individuals in the Brazil Covid 19 trial who did have an adverse side effect, CytoDyn informed the FDA about these incidents and CytoDyn requested that the FDA impose a clinical hold on Leronlimab and that’s what happened.
CytoDyn realized that they were in a lose – lose predicament. CytoDyn knew they would not get an approval no matter what, so they needed to learn why it wouldn’t ever get an FDA approval and the way to do so would be to force the US FDA to tell them what was wrong. So they asked the US FDA that the drug be put on hold. Then they asked the FDA to tell them what needed to be done to get the hold lifted and this forced the US FDA to be actively involved in the approval process of this safe drug.
The US FDA did so. They sat down with CytoDyn and informed them of all the problems with the submitted BLA. They spoke to them about the unformatted raw data and the requirement to get all the data across 22 trials aggregated and formatted into their Type GCP protocol. They informed them of the 5 documents which were mandatory for submission. Nearing the end point where removal of the clinical hold was at hand, the FDA required yet another 6th document to be submitted which was done by March 10, 2023.
Thankfully, CytoDyn brought Cyrus on in the nick of time, near the beginning. Yes, he was hired 7/9/22, but he was there earlier. Cyrus was there just after the hold was implemented and he was involved in devising the exit strategy of this clinical hold. He was the perfect individual for the job. Shareholders should relax, and know that it will succeed, that it will work out for the good. Slow and steady. This is how the US FDA operates, especially, when things go well. When things go bad, it usually is over very quickly, like in the instance of the RTF which happened only days after submission. Here we are at nearly 30 days after submission, and there is no answer from FDA. FDA is looking for reasons for this to fail, but hasn’t found any yet.
The Peer to Peer Reviewed Journal Article that is soon to be published shall provide the true efficacy of Leronlimab in the HIV MDR trial. It shall show that the p value realized in this trial was a 0.032, well below the minimum threshold of 0.05. And the article will be Peer Reviewed, by numerous physicians. It shall be published in a Journal. How would it look if it is published yet, the clinical hold remains in place and not lifted? What could the FDA even say to explain how a Peer Reviewed Published Journal Article is in 180 degree juxtaposition to their pristine judgment, proving that they do not see eye to eye with fellow physicians? Wouldn’t this be a situation that would draw some unwanted attention to the FDA? Attention which the FDA would prefer not to have. They don’t want to reek of the pockets of those who feed them. Their reasoning should be that CytoDyn is far too small to risk your reputation by playing tricks. Also, if we are right in thinking that Merck may want to partner, then by denying CytoDyn, they also deny Merck. Then, Merck would have to come and rescue CytoDyn by assist in getting this over the finish line and Merck would because of Leronlimab’s tested and tried value in combination with Keytruda.
This is just data which needs to be aggregated and properly formatted and put into documents and reports. It is very valuable data worth millions upon millions that proves Leronlimab’s safety. Amarex made it extremely difficult for CytoDyn, damn near impossible, but CytoDyn came through in the end and got it right.
Unless there are ulterior motives, the hold is lifted. Shackles are removed. Which means Leronlimab is back out there doing what it does best. Eradicating tumors, stopping/blocking metastasis, blocking HIV entry, dissolving fibrosis and melting steatosis, allowing healing, etc… The only problem is, that none of the other BP companies want the competition Leronlimab creates. Yes, none except for Merck, if our suspicions are correct. The other BPs want us still locked up, so they have time to come up with a competitor. But, they have nothing on us to keep us locked up. We shall emerge unscathed and stronger than ever. Cyrus has goals and the post-hold CytoDyn will be very busy meeting them and they shall be met, just like this hold lift shall be met, because they know exactly how Leronlimab performs because of the multitude of trials and studies already performed.
CytoDyn has the answer, but unfortunately that answer remains yet locked up in some jail cell. The competition was given a head start, a running start to make their trial attempts to compete with Leronlimab. Lots and lots of fluff is written in attempt to sway the masses. I choose to believe in this CCR5 blockade. This is the true heart of the inflammatory cascade. That is where Leronlimab operates, at the heart of the intra-cellular and immuno-regulatory communication cascade and because there is no competition at this most important level of cellular communication and control and because no other molecule competitively performs a CCR5 blockade like Leronlimab does, especially without any side effects, this molecule IS the answer to a multitude of pathologies as ohm20 has already specified years ago. Yes, their method is to attack each and every pathologic condition by an individual drug and therefore create a multitude of drugs for all the problems. The lonely Leronlimab which is capable of treating all the pathology by its lonesome is in diametric opposition to their plan and to their way of doing things and thinking. They are a diversity capable of only a little with too many side effects, while we are a singularity, capable of much and free of side effects. Our goal is cure and we have it.
submitted by MGK_2 to LeronLimab_Times [link] [comments]
You can just about feel the Momentum building as Rome falls. Out of the center of the picture, a new day appears as the light rays explode through the forest of trees. That Gumbo Truth Pot yet boils, the roux now is good and ready; the lid shimmers as it rattles. Truth is getting ready to explode, oh, on so many different fronts.
Here are the individuals in the leadership team:
https://www.cytodyn.com/our-team/management-team
Here is the Board of Directors:
https://www.cytodyn.com/our-team/board-of-directors
All contributed in one way or another in providing the requested and necessary information to the FDA. Some more than others, but all had a hand in appropriating CytoDyn’s submission into the format required by the FDA. Their natural resource, the raw material supporting their work, providing the backbone of their documents, was the verified and validated, true and clear, aggregated data vetted by the 4 External FDA Type GCP Auditors. That formatted data had eyes on it by 4 different External FDA Auditors. In addition, the Internal Audit team received the raw, unformatted data from Amarex, and assembled it into the aggregated and formatted data employing the overseeing eye of prior FDA regulators.
In my eyes, I don’t believe that the salvage of the raw data begrudgingly provided by Amarex could have been executed with any more painstaking attention to detail, than the way Cyrus accomplished this task. He brought in (4) External FDA Type GCP Auditors who in former times worked for the FDA, and all (4) auditors approved the data as acceptable to the FDA. Then Cyrus used that data in the submitted documents.
We all know that the FDA is not an easy push over. They warned CytoDyn and Amarex in the past that they would surely deliver an RTF if the BLA was not prepared in accordance with their standards. The FDA lived up to that warning which they made. Here, in the case at hand, the FDA requested 5 documents from CytoDyn and nearing the finale, they requested a 6th document. The identity of the 6th document was not revealed, but the good news so far is that, they posed NO questions about the contents of the 5 documents even though they had been reviewing them as early as October 2022. Will they have questions on the 6th document? Will there be a request for a 7th document? So far, none has been asked and it seems as if the time the FDA has to ask that question is just about up.
The FDA has set the rules of play. As long as you play her game the way she says it has to be played, then you can play. She just wants to know that you will engage in the game the way she wants you to play. She should not care about what you did in your former life, but rather should make those judgments based on how you play today. The FDA gave chances to the old boss, but he never learned her game. Things have changed. The FDA has not changed. She will also give a chance to the new boss. Why? Because she has proof that the things she was concerned about have changed. She has been given the evidence in her own language that Leronlimab is safe & sound and that CytoDyn now behaves in accordance with the rules of her game.
Let us all hope that she hasn’t changed her own rules since the writing of these submissions or since the aggregation of the raw data. That wouldn’t be playing fair, but that would be nothing new, would it? Personally, I don’t think she has anything against CytoDyn, after all; aside from Leronlimab, CytoDyn has been revamped from the ground up. CytoDyn should be looked at in the way the 6 documents reflect the company, as if it has a clean, blank slate and that is what was likely submitted, a picture perfect representation. Clean data. Clean papers. The remembrance and recollection of what it once was should be avoided as all the data is presented new and fresh.
If the FDA considers CytoDyn as the same CytoDyn which it had been under Nader, then, they shall find an issue with the submissions. However, the FDA should go about this without any preconceived notions. They should go about this in an unbiased, unprejudiced manner. Lady Liberty is supposed to be blind. Nobody can pursue a matter and no judge can rule over a matter if there is any personal involvement in any way. Here, the FDA has unlimited power because it is their game and if they are biased against CytoDyn, then, they will find an issue with the submissions.
The FDA let this go for way too long. They knew they didn’t have the proof that Leronlimab was safe, but they also knew that they did not have any evidence of any Severe or Adverse Events. So the trials continued. The trials continued to the point that CytoDyn believed that they had what it would take to file a BLA. CytoDyn thought their Leronlimab was safe because the FDA allowed them to carry on their trials. The FDA warned both CytoDyn and Leronlimab that if their data was not in proper order, they would deny the BLA and issue a RTF in its place. Well, the submitted BLA was not up to par, it was not in order, it did not prove that Leronlimab was safe and the FDA issued an RTF. CytoDyn did not have the data proving that Leronlimab was safe.
Despite this ruling, CytoDyn continued along as if the ruling was not even made, even so far as to conduct Covid 19 trials. CytoDyn and shareholders were still thinking that Leronlimab was safe. The truth was that it would have received RTF on even the Covid 19 trials if they too were submitted, because CytoDyn never proved that Leronlimab was safe. As a results of 2 or 3 individuals in the Brazil Covid 19 trial who did have an adverse side effect, CytoDyn informed the FDA about these incidents and CytoDyn requested that the FDA impose a clinical hold on Leronlimab and that’s what happened.
CytoDyn realized that they were in a lose – lose predicament. CytoDyn knew they would not get an approval no matter what, so they needed to learn why it wouldn’t ever get an FDA approval and the way to do so would be to force the US FDA to tell them what was wrong. So they asked the US FDA that the drug be put on hold. Then they asked the FDA to tell them what needed to be done to get the hold lifted and this forced the US FDA to be actively involved in the approval process of this safe drug.
The US FDA did so. They sat down with CytoDyn and informed them of all the problems with the submitted BLA. They spoke to them about the unformatted raw data and the requirement to get all the data across 22 trials aggregated and formatted into their Type GCP protocol. They informed them of the 5 documents which were mandatory for submission. Nearing the end point where removal of the clinical hold was at hand, the FDA required yet another 6th document to be submitted which was done by March 10, 2023.
Thankfully, CytoDyn brought Cyrus on in the nick of time, near the beginning. Yes, he was hired 7/9/22, but he was there earlier. Cyrus was there just after the hold was implemented and he was involved in devising the exit strategy of this clinical hold. He was the perfect individual for the job. Shareholders should relax, and know that it will succeed, that it will work out for the good. Slow and steady. This is how the US FDA operates, especially, when things go well. When things go bad, it usually is over very quickly, like in the instance of the RTF which happened only days after submission. Here we are at nearly 30 days after submission, and there is no answer from FDA. FDA is looking for reasons for this to fail, but hasn’t found any yet.
The Peer to Peer Reviewed Journal Article that is soon to be published shall provide the true efficacy of Leronlimab in the HIV MDR trial. It shall show that the p value realized in this trial was a 0.032, well below the minimum threshold of 0.05. And the article will be Peer Reviewed, by numerous physicians. It shall be published in a Journal. How would it look if it is published yet, the clinical hold remains in place and not lifted? What could the FDA even say to explain how a Peer Reviewed Published Journal Article is in 180 degree juxtaposition to their pristine judgment, proving that they do not see eye to eye with fellow physicians? Wouldn’t this be a situation that would draw some unwanted attention to the FDA? Attention which the FDA would prefer not to have. They don’t want to reek of the pockets of those who feed them. Their reasoning should be that CytoDyn is far too small to risk your reputation by playing tricks. Also, if we are right in thinking that Merck may want to partner, then by denying CytoDyn, they also deny Merck. Then, Merck would have to come and rescue CytoDyn by assist in getting this over the finish line and Merck would because of Leronlimab’s tested and tried value in combination with Keytruda.
This is just data which needs to be aggregated and properly formatted and put into documents and reports. It is very valuable data worth millions upon millions that proves Leronlimab’s safety. Amarex made it extremely difficult for CytoDyn, damn near impossible, but CytoDyn came through in the end and got it right.
Unless there are ulterior motives, the hold is lifted. Shackles are removed. Which means Leronlimab is back out there doing what it does best. Eradicating tumors, stopping/blocking metastasis, blocking HIV entry, dissolving fibrosis and melting steatosis, allowing healing, etc… The only problem is, that none of the other BP companies want the competition Leronlimab creates. Yes, none except for Merck, if our suspicions are correct. The other BPs want us still locked up, so they have time to come up with a competitor. But, they have nothing on us to keep us locked up. We shall emerge unscathed and stronger than ever. Cyrus has goals and the post-hold CytoDyn will be very busy meeting them and they shall be met, just like this hold lift shall be met, because they know exactly how Leronlimab performs because of the multitude of trials and studies already performed.
CytoDyn has the answer, but unfortunately that answer remains yet locked up in some jail cell. The competition was given a head start, a running start to make their trial attempts to compete with Leronlimab. Lots and lots of fluff is written in attempt to sway the masses. I choose to believe in this CCR5 blockade. This is the true heart of the inflammatory cascade. That is where Leronlimab operates, at the heart of the intra-cellular and immuno-regulatory communication cascade and because there is no competition at this most important level of cellular communication and control and because no other molecule competitively performs a CCR5 blockade like Leronlimab does, especially without any side effects, this molecule IS the answer to a multitude of pathologies as ohm20 has already specified years ago. Yes, their method is to attack each and every pathologic condition by an individual drug and therefore create a multitude of drugs for all the problems. The lonely Leronlimab which is capable of treating all the pathology by its lonesome is in diametric opposition to their plan and to their way of doing things and thinking. They are a diversity capable of only a little with too many side effects, while we are a singularity, capable of much and free of side effects. Our goal is cure and we have it.
2023.03.24 23:37 NAKEDnick VR trackers for (mostly) stationary objects
Let’s do the ol’ TL;DR first: I’m looking for thoughts/recommendations for VR trackers to mount to something stationary, like a chair.
Now for the meat and taters: Alright, so I recently built out a flight simpit and wanted to also make it good for VR use. I’ve been playing around with Reality Mixer and have been able to decently bring visibility of my outside control panels into the VR space. It actually works pretty darn well.
The challenge I’m facing is that the simpit itself is on the opposite side of the room from my PC, so I’m at the maximum length of my cable and it puts me at just the right angle to obscure the view of the headset from the base stations.
Now luckily I built my simpit in a way that the displays are completely detached from the main cockpit seat and controls, so my plan is to slide the pit out into the center of the room when I want to do VR, and slot it back in the panel rack for normal use.
Now this is where things get a little murky. Reality Mixer is currently setup with the X-RAY viewports in static locations. This means I have to correct the viewports each time I use it, but also make sure it doesn’t get enabled when I’m playing other VR games.
Luckily, RM supports using trackers to bind the XR windows to a physical object in the real world. So I can just hard mount a tracker to the pit and tie the XR windows to it. Now generally the simplest answer is usually the right answer and in this case it’s using the Vice trackers.
But this is a DIY subreddit, and I’m curious about options for trackers that aren’t geared for being the smallest, lightest, wearables, but rather something that can be biggecumbersome and just hardwired directly into USB for power and communication.
I’ve been scouring the web, and really all I ever find for object trackers is geared at wearable body tracking. Anyone here have some information you might be able to throw my direction?
submitted by NAKEDnick to DIYVRRIGS [link] [comments]
Now for the meat and taters: Alright, so I recently built out a flight simpit and wanted to also make it good for VR use. I’ve been playing around with Reality Mixer and have been able to decently bring visibility of my outside control panels into the VR space. It actually works pretty darn well.
The challenge I’m facing is that the simpit itself is on the opposite side of the room from my PC, so I’m at the maximum length of my cable and it puts me at just the right angle to obscure the view of the headset from the base stations.
Now luckily I built my simpit in a way that the displays are completely detached from the main cockpit seat and controls, so my plan is to slide the pit out into the center of the room when I want to do VR, and slot it back in the panel rack for normal use.
Now this is where things get a little murky. Reality Mixer is currently setup with the X-RAY viewports in static locations. This means I have to correct the viewports each time I use it, but also make sure it doesn’t get enabled when I’m playing other VR games.
Luckily, RM supports using trackers to bind the XR windows to a physical object in the real world. So I can just hard mount a tracker to the pit and tie the XR windows to it. Now generally the simplest answer is usually the right answer and in this case it’s using the Vice trackers.
But this is a DIY subreddit, and I’m curious about options for trackers that aren’t geared for being the smallest, lightest, wearables, but rather something that can be biggecumbersome and just hardwired directly into USB for power and communication.
I’ve been scouring the web, and really all I ever find for object trackers is geared at wearable body tracking. Anyone here have some information you might be able to throw my direction?
2023.03.24 21:25 Vladus99 Every Steelers Offense Ranked by Points Per Game
The other day somebody asked what was the best offense in team history, and while there were several different answers provided, the most common denominator were the Killer B's of the mid 2010's. It got me wondering how all of our offenses compare to each other throughout the years.
I decided to rank offenses by points scored per game since, at the end of the day, your main goal is to score more points than the other team. Of course, this is a flawed measurement since it doesn't take into account points scored by defense and special teams, as well as how often the offense was placed in good position to score points. Regardless, the ability to score is incredibly important, so this will be the metric for this little analysis.
In addition to their ppg, I also included their record, the amount of games played, the total points they scored, and how they ranked amongst the rest of the NFL. For example, the most recent team, the 2022 Steelers, scored 308 points in 17 games, averaging to 18.1 ppg, which ranked 26th out of 32 teams that year. Despite the poor offense, they finished with a winning record and missed the postseason on tiebreakers.
Here are the detailed results below:
Not surprising that five of the top ten spots are occupied by the Killer B's offenses of the 2010's, with a couple of the Super Bowl teams from the '70s appearing as well. The bottom ten spots are primarily occupied by the Pirates teams and a few WW2 era squads, including the Card-Pitt merger, which is debatably the worst pool of talent in NFL history.
The worst ranked team here is the 1934 Steelers, or as they were known as back then, the Pirates. In just their second year as a franchise, the Pirates boasted an offense that scored all of 6 TD's on the season, with their leading scorer being E Joe Skladany, who scored 12 of their 51 points. They opened the season with a 13-0 win against the Cincinnati Reds then proceeded to top double digit points only once the rest of the season, which featured 6 shutouts. The offense itself was actually fairly decent at moving the ball downfield (they finished the season ranking 4th out of 11 in yards per play), thanks in large part to TB Warren Heller ranking as one of the league's top passers and rushers. Unfortunately, a penchant for turnovers along with an inability to capitalize in the redzone meant that the Pirates finished the season as one of the worst teams in the league.
The most surprising team to finish in the top 10 are the 1952 Steelers, the highest ranked team on here with a losing record. Even though they went 5-7, five of their losses were one possession games, so the Steelers were a very competitive unit that season. This was the first year they used the T-formation, with QB Jim Finks throwing a league leading 20 TD's and setting several team records in passing along the way. Flanking him were a pair of dynamic backs in Ray Mathews and Lynn Chandnois, who were efficient dual-threat weapons on offense (Mathews led the NFL in yards per touch) and lethal return specialists on special teams, combining for 3,000 all-purpose yards. Rounding out the offensive attack was TE Elbie Nickel, who set team records in receptions (55), receiving yards (884), and receiving TD's (9). All four of these players made the Pro Bowl that year. This team also produced the biggest victory in franchise history when they beat the Giants 63-7 in week 10.
The lowest ranked team to finish with a winning record are the 1942 Steelers, coincidentally the first team in franchise history to post a winning record. Even though they're in the bottom 20 of this list, they still finished 4th in scoring that season (although the gap between them and 3rd place was 60 points) and had the second best rushing attack in the NFL that year. The main catalyst for this team was TB Bill Dudley, the top pick in the draft that year who led the NFL in rushing yards and was also a top flight DB and return specialist. Aiding him was a backfield featuring FB Dick Riffle (heh), a great complimentary runner to Dudley, and HB Curt Sandig, who was also the team's primary punter. The big weakness of the offense was their kicking. While they finished a respectable 20/23 on extra points, they went a whopping 3/16 on field goal attempts. Normally reliable Armand Niccolai announced his retirement in the offseason, but when players began to enlist in the army during WW2, he was given the offer of a lifetime: play strictly as a kicker without having to attend practice or training camp. A sweet deal, except it led to Niccolai completing an atrocious 2/14 field goals that year. 1940's NFL!
In the entire history of the Steelers, they've finished 1st in points scored only once in 1979. Coming off their 3rd Super Bowl win of the decade, the '79 squad would repeat as champs by finishing with one of the best offenses in team history. Terry Bradshaw followed up his MVP '78 season by throwing for over 3,700 yards and 26 TD's... and 25 INT's. Franco Harris posted his sixth straight 1,000 yard season, averaging 4.4 yards per carry and scoring 12 TD's, with Rocky Bleier and Sidney Thornton providing additional support in the backfield combining for 12 TD's of their own. Lynn Swann and John Stallworth were one of the top receiving tandems in the league, combining for nearly 2,000 receiving yards and 13 TD's. Perhaps the most impressive feat of this offense is that they managed to lead the league in points and yards while also committing 52 TURNOVERS. Despite turning over the ball more than any other team in the NFL, they still had the best offense in the league. That's just how mighty the Steelers were back then.
On the opposite end of the spectrum, there have been a whopping 10 occasions where the Steelers offense ranked dead last in scoring: '38, '40, '41, '44, '45, '46, '50, '55, '57, and '65. I'm not gonna take the time to detail every specific one, but I wanna give special mention to the '57 Steelers. They finished the season with a 6-6 record and a defense that ranked first in yards and second in points allowed. They had debatably the best defense in the NFL, but they were dragged down exponentially by one of the worst offenses in league history. This isn't an exaggeration, btw. Their passing game, led by Earl Morrall before he became a journeyman, finished with a lousy 4.9 net yards per attempt (which ranked 11th out of 12 teams, ouch). But what really separates this squad as one of the worst is their ground game, which averaged all of 3.0 yards per carry and was dead last in the NFL by nearly a full yard. Additionally, DVOA has this team ranked as the second worst rushing offense in NFL history. Their leading rusher, Billy Wells, only had 532 yards, averaged 3.5 yards per attempt, and didn't score once all season. To give an idea how bad this offense was, the Steelers defense allowed the fewest touchdowns in the league with only 21. The Steelers offense, meanwhile, scored the fewest touchdowns in the NFL with 20. Pathetic.
So that's the breakdown and a mini analysis of a few teams on here for you. Thank you for reading, and thank you Reddit editor for being a pain in my ass trying to make this.
submitted by Vladus99 to steelers [link] [comments]
I decided to rank offenses by points scored per game since, at the end of the day, your main goal is to score more points than the other team. Of course, this is a flawed measurement since it doesn't take into account points scored by defense and special teams, as well as how often the offense was placed in good position to score points. Regardless, the ability to score is incredibly important, so this will be the metric for this little analysis.
In addition to their ppg, I also included their record, the amount of games played, the total points they scored, and how they ranked amongst the rest of the NFL. For example, the most recent team, the 2022 Steelers, scored 308 points in 17 games, averaging to 18.1 ppg, which ranked 26th out of 32 teams that year. Despite the poor offense, they finished with a winning record and missed the postseason on tiebreakers.
Here are the detailed results below:
| Rank | Year | Points Per Game | Games Played | Record | Points Scored | League Rankings |
|---|---|---|---|---|---|---|
| 1. | 2014 | 27.3 | 16 | 11-5 | 436 | 7/32 |
| 2. | 2018 | 26.8 | 16 | 9-6-1 | 428 | 6/32 |
| 3. | 1975 | 26.6 | 14 | 12-2 | 373 | 5/26 |
| 4. | 2015 | 26.4 | 16 | 10-6 | 423 | 4/32 |
| T/5. | 2020 | 26.0 | 16 | 12-4 | 416 | 12/32 |
| T/5. | 1979 | 26.0 | 16 | 12-4 | 416 | 1/28 |
| T/7. | 1995 | 25.4 | 16 | 11-5 | 407 | 5/30 |
| T/7. | 2017 | 25.4 | 16 | 13-3 | 406 | 8/32 |
| 9. | 1952 | 25.0 | 12 | 5-7 | 300 | 4/12 |
| 10. | 2016 | 24.9 | 16 | 11-5 | 399 | 10/32 |
| 11. | 1973 | 24.8 | 14 | 10-4 | 347 | 4/26 |
| 12. | 2007 | 24.6 | 16 | 10-6 | 393 | 9/32 |
| 13. | 1972 | 24.5 | 14 | 11-3 | 343 | 5/26 |
| T/14. | 2002 | 24.4 | 16 | 10-5-1 | 390 | 8/32 |
| T/14. | 1976 | 24.4 | 14 | 10-4 | 342 | 5/28 |
| 16. | 2005 | 24.3 | 16 | 11-5 | 389 | 9/32 |
| 17. | 1984 | 24.2 | 16 | 9-7 | 387 | 8/28 |
| T/18. | 2013 | 23.7 | 16 | 8-8 | 379 | 16/32 |
| T/18. | 1985 | 23.7 | 16 | 7-9 | 379 | 9/28 |
| 20. | 2010 | 23.4 | 16 | 12-4 | 375 | 12/32 |
| T/21. | 2004 | 23.3 | 16 | 15-1 | 372 | 11/32 |
| T/21. | 1997 | 23.3 | 16 | 11-5 | 372 | 7/30 |
| 23. | 2009 | 23.0 | 16 | 9-7 | 368 | 12/32 |
| 24. | 1963 | 22.9 | 14 | 7-4-3 | 321 | 6/14 |
| 25. | 1982 | 22.7 | 9 | 6-3 | 204 | 8/28 |
| 26. | 1966 | 22.6 | 14 | 5-8-1 | 316 | 7/15 |
| 27. | 1943 (Steagles) | 22.5 | 10 | 5-4-1 | 225 | 4/10 |
| T/28. | 1981 | 22.3 | 16 | 8-8 | 356 | 8/28 |
| T/28. | 1978 | 22.3 | 16 | 14-2 | 356 | 5/28 |
| T/28. | 1962 | 22.3 | 14 | 9-5 | 312 | 6/14 |
| 31. | 1983 | 22.2 | 16 | 10-6 | 355 | 14/28 |
| 32. | 2006 | 22.1 | 16 | 8-8 | 353 | 12/32 |
| T/33. | 2001 | 22.0 | 16 | 13-3 | 352 | 7/31 |
| T/33. | 1980 | 22.0 | 16 | 9-7 | 352 | 10/28 |
| T/35. | 1974 | 21.8 | 14 | 10-3-1 | 305 | 6/26 |
| T/35. | 1958 | 21.8 | 12 | 7-4-1 | 261 | 5/12 |
| 37. | 2008 | 21.7 | 16 | 12-4 | 347 | 20/32 |
| 38. | 1996 | 21.5 | 16 | 10-6 | 344 | 11/30 |
| 39. | 1959 | 21.4 | 12 | 6-5-1 | 257 | 5/12 |
| 40. | 1961 | 21.1 | 14 | 6-8 | 295 | 8/14 |
| T/41. | 2012 | 21.0 | 16 | 8-8 | 336 | 22/32 |
| T/41. | 1988 | 21.0 | 16 | 5-11 | 336 | 13/28 |
| 43. | 2011 | 20.3 | 16 | 12-4 | 325 | 21/32 |
| T/44. | 2021 | 20.2 | 17 | 9-7-1 | 343 | 21/32 |
| T/44. | 1977 | 20.2 | 14 | 9-5 | 283 | 7/28 |
| T/46. | 2000 | 20.1 | 16 | 9-7 | 321 | 17/31 |
| T/46. | 1967 | 20.1 | 14 | 4-9-1 | 281 | 10/16 |
| T/48. | 1960 | 20.0 | 12 | 5-6-1 | 240 | 9/13 |
| T/48. | 1947 | 20.0 | 12 | 8-4 | 240 | 7/10 |
| T/50. | 1999 | 19.8 | 16 | 6-10 | 317 | 17/31 |
| T/50. | 1994 | 19.8 | 16 | 12-4 | 316 | 16/28 |
| 52. | 1993 | 19.3 | 16 | 9-7 | 308 | 13/28 |
| 53. | 1986 | 19.2 | 16 | 6-10 | 307 | 18/28 |
| 54. | 1987 | 19.0 | 15 | 8-7 | 285 | 20/28 |
| 55. | 2003 | 18.8 | 16 | 6-10 | 300 | 19/32 |
| T/56. | 1992 | 18.7 | 16 | 11-5 | 299 | 15/28 |
| T/56. | 1949 | 18.7 | 12 | 6-5-1 | 224 | 8/10 |
| T/58. | 1991 | 18.3 | 16 | 7-9 | 292 | 17/28 |
| T/58. | 1990 | 18.3 | 16 | 9-7 | 292 | 20/28 |
| T/58. | 1954 | 18.3 | 12 | 5-7 | 219 | 9/12 |
| T/61. | 2022 | 18.1 | 17 | 9-8 | 308 | 26/32 |
| T/61. | 2019 | 18.1 | 16 | 8-8 | 289 | 27/32 |
| T/61. | 1964 | 18.1 | 14 | 5-9 | 253 | 11/14 |
| T/61. | 1956 | 18.1 | 12 | 5-7 | 217 | 9/12 |
| T/65. | 1971 | 17.6 | 14 | 6-8 | 246 | 17/26 |
| T/65. | 1953 | 17.6 | 12 | 6-6 | 211 | 7/12 |
| 67. | 1968 | 17.4 | 14 | 2-11-1 | 244 | 13/16 |
| 68. | 1948 | 16.7 | 12 | 4-8 | 200 | 7/10 |
| 69. | 1989 | 16.6 | 16 | 9-7 | 265 | 24/28 |
| 70. | 1998 | 16.4 | 16 | 7-9 | 263 | 28/30 |
| 71. | 1955 | 16.3 | 12 | 4-8 | 195 | 12/12 |
| 72. | 1969 | 15.6 | 14 | 1-13 | 218 | 15/16 |
| 73. | 1951 | 15.3 | 12 | 4-7-1 | 183 | 11/12 |
| 74. | 1942 | 15.2 | 11 | 7-4 | 167 | 4/10 |
| T/75. | 1970 | 15.0 | 14 | 5-9 | 210 | 21/26 |
| T/75. | 1950 | 15.0 | 12 | 6-6 | 180 | 13/13 |
| 77. | 1965 | 14.4 | 14 | 2-12 | 202 | 14/14 |
| 78. | 1957 | 13.4 | 12 | 6-6 | 161 | 12/12 |
| 79. | 1946 | 12.4 | 11 | 5-5-1 | 136 | 10/10 |
| 80. | 1937 | 11.1 | 11 | 4-7 | 122 | 7/10 |
| 81. | 1944 (Card-Pitt) | 10.8 | 10 | 0-10 | 108 | 10/10 |
| 82. | 1939 | 10.4 | 11 | 1-9-1 | 114 | 7/10 |
| 83. | 1941 | 9.4 | 11 | 1-9-1 | 103 | 10/10 |
| 84. | 1935 | 8.3 | 12 | 4-8 | 100 | 5/9 |
| 85. | 1936 | 8.2 | 12 | 6-6 | 98 | 6/9 |
| 86. | 1945 | 7.9 | 10 | 2-8 | 79 | 10/10 |
| 87. | 1938 | 7.2 | 11 | 2-9 | 79 | 10/10 |
| 88. | 1933 | 6.1 | 11 | 3-6-2 | 67 | 8/10 |
| 89. | 1940 | 5.5 | 11 | 2-7-2 | 60 | 10/10 |
| 90. | 1934 | 4.3 | 12 | 2-10 | 51 | 10/11 |
A miniature breakdown of a few notable seasons
The best ranked team here is the 2014 Steelers, whose 436 points only ranked 7th out of 32 teams, but they gained the 2nd most yards of offense thanks to Ben Roethlisberger having the best season of his career, throwing a league best 4,932 passing yards along with 32 TD's, including a stretch where Big Ben threw 6 TD's in consecutive games. Alongside Ben were All-Pros Le'Veon Bell and Antonio Brown, who combined for over 3,900 scrimmage yards and 24 TD's. Assisting them were Markus Wheaton and Martavis Bryant, who were solid receivers playing opposite AB, and the ever-so-reliable Heath Miller at tight end. Add in Shaun Suisham converting 29/32 field goals and all of his PAT's, and you have the highest scoring offense in team history.The worst ranked team here is the 1934 Steelers, or as they were known as back then, the Pirates. In just their second year as a franchise, the Pirates boasted an offense that scored all of 6 TD's on the season, with their leading scorer being E Joe Skladany, who scored 12 of their 51 points. They opened the season with a 13-0 win against the Cincinnati Reds then proceeded to top double digit points only once the rest of the season, which featured 6 shutouts. The offense itself was actually fairly decent at moving the ball downfield (they finished the season ranking 4th out of 11 in yards per play), thanks in large part to TB Warren Heller ranking as one of the league's top passers and rushers. Unfortunately, a penchant for turnovers along with an inability to capitalize in the redzone meant that the Pirates finished the season as one of the worst teams in the league.
The most surprising team to finish in the top 10 are the 1952 Steelers, the highest ranked team on here with a losing record. Even though they went 5-7, five of their losses were one possession games, so the Steelers were a very competitive unit that season. This was the first year they used the T-formation, with QB Jim Finks throwing a league leading 20 TD's and setting several team records in passing along the way. Flanking him were a pair of dynamic backs in Ray Mathews and Lynn Chandnois, who were efficient dual-threat weapons on offense (Mathews led the NFL in yards per touch) and lethal return specialists on special teams, combining for 3,000 all-purpose yards. Rounding out the offensive attack was TE Elbie Nickel, who set team records in receptions (55), receiving yards (884), and receiving TD's (9). All four of these players made the Pro Bowl that year. This team also produced the biggest victory in franchise history when they beat the Giants 63-7 in week 10.
The lowest ranked team to finish with a winning record are the 1942 Steelers, coincidentally the first team in franchise history to post a winning record. Even though they're in the bottom 20 of this list, they still finished 4th in scoring that season (although the gap between them and 3rd place was 60 points) and had the second best rushing attack in the NFL that year. The main catalyst for this team was TB Bill Dudley, the top pick in the draft that year who led the NFL in rushing yards and was also a top flight DB and return specialist. Aiding him was a backfield featuring FB Dick Riffle (heh), a great complimentary runner to Dudley, and HB Curt Sandig, who was also the team's primary punter. The big weakness of the offense was their kicking. While they finished a respectable 20/23 on extra points, they went a whopping 3/16 on field goal attempts. Normally reliable Armand Niccolai announced his retirement in the offseason, but when players began to enlist in the army during WW2, he was given the offer of a lifetime: play strictly as a kicker without having to attend practice or training camp. A sweet deal, except it led to Niccolai completing an atrocious 2/14 field goals that year. 1940's NFL!
In the entire history of the Steelers, they've finished 1st in points scored only once in 1979. Coming off their 3rd Super Bowl win of the decade, the '79 squad would repeat as champs by finishing with one of the best offenses in team history. Terry Bradshaw followed up his MVP '78 season by throwing for over 3,700 yards and 26 TD's... and 25 INT's. Franco Harris posted his sixth straight 1,000 yard season, averaging 4.4 yards per carry and scoring 12 TD's, with Rocky Bleier and Sidney Thornton providing additional support in the backfield combining for 12 TD's of their own. Lynn Swann and John Stallworth were one of the top receiving tandems in the league, combining for nearly 2,000 receiving yards and 13 TD's. Perhaps the most impressive feat of this offense is that they managed to lead the league in points and yards while also committing 52 TURNOVERS. Despite turning over the ball more than any other team in the NFL, they still had the best offense in the league. That's just how mighty the Steelers were back then.
On the opposite end of the spectrum, there have been a whopping 10 occasions where the Steelers offense ranked dead last in scoring: '38, '40, '41, '44, '45, '46, '50, '55, '57, and '65. I'm not gonna take the time to detail every specific one, but I wanna give special mention to the '57 Steelers. They finished the season with a 6-6 record and a defense that ranked first in yards and second in points allowed. They had debatably the best defense in the NFL, but they were dragged down exponentially by one of the worst offenses in league history. This isn't an exaggeration, btw. Their passing game, led by Earl Morrall before he became a journeyman, finished with a lousy 4.9 net yards per attempt (which ranked 11th out of 12 teams, ouch). But what really separates this squad as one of the worst is their ground game, which averaged all of 3.0 yards per carry and was dead last in the NFL by nearly a full yard. Additionally, DVOA has this team ranked as the second worst rushing offense in NFL history. Their leading rusher, Billy Wells, only had 532 yards, averaged 3.5 yards per attempt, and didn't score once all season. To give an idea how bad this offense was, the Steelers defense allowed the fewest touchdowns in the league with only 21. The Steelers offense, meanwhile, scored the fewest touchdowns in the NFL with 20. Pathetic.
So that's the breakdown and a mini analysis of a few teams on here for you. Thank you for reading, and thank you Reddit editor for being a pain in my ass trying to make this.